Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Abstract:
Spectrum Pharmaceuticals, Inc. has acquired all the patent rights associated with Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies, Inc., a manufacturer of nanomaterials and nano-based products. Spectrum Pharmaceuticals is a biotechnology company focused on Oncology. Both the companies are based in the US.

Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Irvine, CA | Posted on August 10th, 2009

This agreement amends and restates an existing, limited licensing agreement between Spectrum and Altair, for Renazorb(TM) and Renalan(TM) compound. Spectrum will now have exclusive worldwide rights to Renazorb(TM), Renalan(TM), and any related compounds in any field of use.

Under terms of the agreement, Altair would receive $0.75 million in Spectrum restricted common stock. In addition to the royalty and other payments, Altair was to receive under the prior license agreement. Altair would now receive 10% of any fees Spectrum may receive from the sub-licensing of Renazorb(TM), Renalan(TM), and any related compounds.

Update on June 7, 2006:

Altair announced it would receive 0.1 million shares of Spectrum stock for a milestone payment and an additional 0.04 million shares for product development improvements, with a total approximate value of $0.55 million, following a mutually agreed upon resolution to arbitration proceedings involving the two companies. Altair and Spectrum would continue efforts to move the RenaZorb product technology to market quickly.

Announcement (January 31, 2005):

Spectrum has acquired worldwide exclusive rights to RenaZorb (two second-generation lanthanum-based phosphate binding agents) from Altair. These novel non-aluminum, non-calcium phosphate binders which utilize Altair' proprietary lanthanum nanomaterial technology have the potential to treat hyperphosphatemia, in patients with end-stage renal disease and chronic kidney disease.

Under the terms of the agreement, Spectrum acquired an exclusive worldwide license to develop and commercialize RenaZorb(TM) for all human therapeutic and diagnostic uses. In return, Spectrum would pay to Altair an upfront payment of 0.1 million shares of restricted Spectrum common stock and would make an equity investment of $0.2 million for 38,314 shares of Altair common stock. In addition, Altair would be eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales.

####

About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.

For more information, please click here

Contacts:
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706

Copyright © tradingmarkets.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Spectrum Pharmaceuticals

Related News Press

News and information

Meteorite impact on a nano scale August 29th, 2016

Designing ultrasound tools with Lego-like proteins August 29th, 2016

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

Investments/IPO's/Splits

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Carbodeon Ltd Oy Closes EUR 1.5 million Funding Round From Straightforward Capital: Carbodeon will accelerate its nanodiamonds business and expand manufacturing capacity August 21st, 2016

Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016

Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016

Nanomedicine

Designing ultrasound tools with Lego-like proteins August 29th, 2016

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

Announcements

Meteorite impact on a nano scale August 29th, 2016

Designing ultrasound tools with Lego-like proteins August 29th, 2016

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Patents/IP/Tech Transfer/Licensing

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Integration of novel materials with silicon chips makes new 'smart' devices possible July 25th, 2016

Research team led by NUS scientists develop plastic flexible magnetic memory device: Novel technique to implant high-performance magnetic memory chip on a flexible plastic surface without compromising performance July 21st, 2016

Nanobiotechnology

Designing ultrasound tools with Lego-like proteins August 29th, 2016

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic